B+
Bull case
25%
Probability
Target price
$86.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
BMRN
BioMarin PharmaceuticalANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 revenue beat, raised FY26 guidance, strong VOXZOGO demand, and potential hypochondroplasia expansion provide a credible positive setup. Amicus integration could broaden growth and improve profitability if execution is strong [#SEC-8K-2026-08-06].
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-08.
What can break
Clinical-data or regulatory-execution risk around the hypochondroplasia program.
Momentum
56
Value
64
Sentiment
77
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $73.00 · Bull $86.00 · Bear $54.00Analysis 2026-09-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $91.48
Why
Momentum56 · Δ7d +3.2
Value64 · Δ7d -0.0
Sentiment77 · Δ7d +5.9
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-08.
- • Sentiment remains the lead driver in the composite, 7D delta +5.9.
Contradictions & invalidation
- • Clinical-data or regulatory-execution risk around the hypochondroplasia program.
- • FDA review, timing, or approval risk for the VOXZOGO hypochondroplasia sNDA.
- • The recent earnings catalyst appears substantially priced in, while the larger upside depends on regulatory progress, clinical-data reception, and successful Amicus integration.
Catalyst clock
2026-08-06
Q2 2026 beat and raised FY26 guidance
Lead driver: Sentiment · See AI snapshot
Momentum
56
9% active weight
Current posture
7d trendImproving
Δ7d
+3.2
Δ21d
-23.9
Value
64
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
77
62% active weight
Current posture
7d trendImproving
Δ7d
+5.9
Δ21d
+4.1
Why this grade
Composite grade A. Momentum 55.9 / Value 64.1 / Sentiment 77.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$12.9B
Beta
0.26
Shares Out
193.57M
P/E (TTM)
22.1
P/S (TTM)
3.66
P/FCF (TTM)
13.70
Rev YoY
+20.4%
EPS YoY
-81.3%
Gross Margin
+73.9%
Op Margin
+18.5%
Net Debt
-$917.74M
Current Ratio
2.39
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data